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The assessment of risks to human health associated with exposure to oxidant air pollutants has not received adequate attention despite the recog-
nized public health threat posed by the ubiquitous presence of these compounds in the environment. In this article, research needs and uncertain-
ties at each of the steps in the risk assessment of oxidant air pollutants are identified: hazard identification, dose-response assessment, exposure
assessment, and risk characterization. Many of these limitations and uncertainties arise at the interface between the laboratory and the regulatory
arenas. Therefore, as a case study, relevant methodologic problems associated with the application of experimental findings to the risk assessment
of respirable dusts are also discussed. These issues include the extrapolation of animal data to the human case and extrapolation from high-dose to
environmentally relevant, low-level exposures. - Environ Health Perspect 102(Suppl 10):209-214 (1994)
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Introduction
A significant part ofthe population is rou-
tinely exposed to ambient air pollutants
that have oxidizing properties. These ambi-
ent oxidants include photochemical oxi-
dant pollutants, such as ozone (03) (1-3)
and the nitrogen oxides NO2 and NO
(NO ) (4), as well as certain mineral dusts
that can act in part by oxidant mecha-
nisms, such as crystalline silica (5,6) and
asbestos (7). The ubiquitous nature of
ambient oxidants in the environment is
underscored by estimations that over 100
million Americans are exposed to levels of
03 that exceed the current National
Ambient Air Quality Standard (8), and
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that a normal human lung contains up to
two million asbestos fibers per gram ofdry
tissue (9,10).
Numerous toxicologic and epidemio-
logic studies have demonstrated adverse
health effects as a consequence ofexposure
to oxidant pollutants at environmentally
relevant concentrations, and the presence
of oxidant pollutants in the troposphere
has long been recognized as a public health
concern. However, there have been few
studies directly aimed at improving the
assessment of risks that these compounds
pose to human health. In this article we
outline the process of risk assessment as it
is currently practiced by regulatory agencies
in the United States. We also identify spe-
cific areas ofinvestigation where additional
information is needed to undertake studies
on the health risks presented by exposure
to oxidant pollutants found in ambient air.
As a case study, relevant methodologic
problems in the application of laboratory
findings to risk assessment are then illus-
trated in a discussion of the toxicology of
respirable dusts.
The Risk Assessment Process
Risk assessment is a process that leads to an
estimation ofthe probability that an unto-
ward effect will result from exposure to a
substance given a defined set of circum-
stances. Although the terms are sometimes
used interchangeably, risk assessment is a
process distinct from that of risk manage-
ment, the latter uses the results of a risk
assessment in the development of policies
aimed at identifying and reducing risks.
The paradigm for risk assessment that is
most widely used in the United States was
first put forth by a 1983 National Research
Council report that has come to be known
as the "Red Book" (11). Essentially, the
process consists offour steps: hazard identi-
fication, dose-response assessment, expo-
sure assessment, and risk characterization.
As the initial step, hazard identification
establishes a preliminary causative link
between exposure to a chemical and a spe-
cific deleterious effect on health. The types
of scientific information used in a hazard
identification include epidemiologic, ani-
mal toxicity, and in vitro toxicity data. In
addition, findings derived from structure-
activity relationships and computer model-
ing sometimes are used.
What is sought in conducting a dose-
response assessment is a description of the
quantitative relationship that exists between
exposure to a compound and the nature,
incidence, or severity of a specific toxic
outcome of that exposure. Data for this
step typically are drawn from two sources:
experimental animal studies and, preferably
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but more rarely, human data derived from
accidental, occupational, or controlled
human exposures. It is worth emphasizing
that separate dose-response assessments are
needed for each end point of toxicity.
These data evaluations then are used as a
basis for the various extrapolations and
assumptions that risk assessors have to
make when faced with significant gaps in
the knowledge base ofthe adverse effects of
the chemical/physical agent in question.
This facet of the dose-response assessment
is often the most contentious step in the
risk assessment process.
Exposure assessment concerns the iden-
tification and characterization ofthe popu-
lations exposed and determines the
magnitude and duration of the exposure.
This step relies on demographic analysis
and environmental monitoring and is often
the most neglected aspect of risk assess-
ment, mainly because often much of the
information needed is unavailable. Finally,
in the risk characterization phase, the
results ofthe first three steps are integrated
to produce an estimate of the likelihood
that an adverse health effect will occur, and
the frequency and severity with which the
outcome can be expected in the population
under specified conditions.
Issues in the Risk Assessment
of Oxidants
A pivotal part of any hazard assessment is
the identification of specific and relevant
end points of toxicity. In that regard, the
hazard identification for most ambient oxi-
dant pollutants has in part already been
done, since untoward effects have already
been associated with exposure to these
agents. Because the principal route ofexpo-
sure to oxidant pollutants is inhalation, the
respiratory tract is the most relevant target
of their toxicity. However, other sources
such as ingestion or dermal exposure also
could be important. The pulmonary toxi-
cology end points produced by oxidant
exposure can be categorized as those that
result from acute exposure and those pro-
duced by chronic exposure.
A list of the acute end points would
include: pulmonary function changes, pul-
monary edema, the presence of inflamma-
tory cells or inflammatory mediators in
bronchoalveolar lavage fluid (BALF),
changes in the content of antioxidants in
BALF, evidence of genetic damage that
may be apparent in lung cells obtained by
lavage, biomarkers ofoxidant damage such
as pentane and aldehydes in exhaled
breath, effects on host defense mechanisms,
and changes in the redox status of lung
cells that may provide evidence of acceler-
ated aging or "toxic senescence" in the
lung. This list is not complete and other
end points could well be added to it (12).
End points of chronic exposure could
include all of the changes under the acute
category in addition to alterations in lung
morphology, and other parameters that
may suggest obstructive, restrictive, or neo-
plastic disease in the lung as a consequence
ofexposure to ambient oxidants. The haz-
ard identification of oxidant pollutants
would be greatly facilitated if one or more
end points oftoxicity common to all envi-
ronmental oxidants could be identified,
since this would make it possible to treat
oxidants as a class ofcompounds and possi-
bly permit ranking them according to their
potency.
The dose-response assessment for a
specific toxic end point that results from
exposure to an ambient oxidant would be
the next step undertaken in a risk assess-
ment study. Fortunately, many of the oxi-
dants are relatively well-studied
compounds. For certain oxidants such as
03, a substantial amount ofhuman data at
environmentally relevant concentrations
already exists. These data are derived from
studies of occupational exposures in the
case of asbestos and from controlled
human exposure studies in the case of 03
and NO. There are also a significant
amount of animal data, including findings
from chronic exposures to some oxidants.
In addition, the recent introduction of
techniques that use nonradioactive isotopes
of oxygen promises to elucidate the rela-
tionship that exists between exposure con-
centration and the dose that actually is
delivered to the relevant parts ofthe respi-
ratory tract (13). In spite of this progress,
however, there are also several unresolved
issues surrounding the dose-response
assessment of oxidants. For example, if a
common end point of toxicity can be
found for some oxidants, can a dose equiv-
alency for exposure to them be calculated?
If so, is the redox potential of an oxidant
predictive ofits potency as an oxidant? And
last, how should we deal with oxidant
injury caused by inflammatory cells
attracted to the site of injury by the initial
oxidant insult to the lung?
The exposure assessment of many oxi-
dant pollutants also presents challenges.
For example, epidemiologic evidence sug-
gests that certain segments of the popula-
tion are at a higher risk of injury by
exposure to ambient oxidants; for example,
the elderly (14), children (15), and people
with existing pulmonary conditions such as
asthma (16) or respiratory allergies (17).
More data on the nature ofthe exposure of
these and other segments ofthe population
that might be especially susceptible are
needed. The role ofdietary factors, specifi-
cally dietary antioxidants, needs elucidation
in view ofepidemiologic studies that show
an increased risk ofvarious types ofcancer
associated with antioxidant vitamin defi-
ciencies (18,19). Another issue that has
been discussed is the appropriateness ofthe
current monitoring and regulatory strate-
gies. Currently exposure limits for pollu-
tants such as 03 are given as a "maximum
one-hour exposure level." However, results
from animal exposure studies argue in
favor of using an approach that also takes
into account cumulative exposure and the
episodic nature of environmental exposure
to air pollutants (20).
Areas of research that would produce
information applicable to all stages of the
risk assessment ofoxidant pollutants can be
categorized only in broad terms here. More
data on basic mechanisms ofinflammation
in the lung would be helpful for two rea-
sons. First, much additional information is
needed before it is possible to distinguish
between oxidant injury that is produced by
exposure to oxidant compounds and that
which is caused by inflammatory cells
migrating to the site ofinjury. Second, cur-
rent information indicates that some type
of inflammatory response is an end point
common to the pulmonary toxicity of
most, ifnot all, ofthe ambient oxidants.
Reliable biomarkers ofexposure to oxi-
dants are also needed to facilitate the dose-
response and exposure assessments. For
obvious reasons, noninvasive biomarkers,
such as markers oflipid peroxidation (e.g.,
pentane) found in exhaled breath, are the
preferred type. Finally, much more infor-
mation is needed on the effects of chronic
exposure to low, environmentally relevant
concentrations of oxidant, given that this
pattern of exposure describes that which
affects large segments ofthe population. In
particular, the effects of repeated or sus-
tained exposures to low levels of oxidants
on lung connective tissue and the possible
role of oxidants as carcinogens or tumor
promoters needs elucidation.
Pulmonary Toxicology of
Inhaled Particles: Lessonsfor
Risk Assessment
The process ofrisk assessment described in
the preceding paragraphs poses a number
ofproblems, some ofwhich can be summa-
rized with the following questions. First,
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for a given material or toxic response,
which animal species is most appropriate
for extrapolation to human health risk
assessment? Second, given that most expo-
sure studies are performed in healthy
inbred animals, how relevant are these
results to predicting effects in humans who
show wide genetic variability and may have
compromised health? Third, how appropri-
ate is the assumption that the mechanisms
leading to a specific toxic response in
experimental animals are the same in
humans? Fourth, which mathematic model
should we use to address the crucial issues
of high-to-low exposure and animal-to-
human extrapolations? In this section, the
example of pulmonary effects of inhaled
particulate compounds will be used to dis-
cuss these questions.
Recent epidemiologic studies suggest
that levels of total suspended particle con-
centrations at or below the current
National Ambient Air Quality Standard of
150 4g/m3 cause increased morbidity and
mortality in humans. There is evidence
that these effects occur at particle levels as
low as 50 jg/mi3, a concentration that does
not appear to have any effect in laboratory
animals. A key question is whether this is a
real effect that can be causally connected to
ambient particle air concentrations. While
the correlation between morbidity/mortal-
ity and exposure to airborne particles may
be clearly established from epidemiologic
studies (21,22), such evidence can not
prove causality. Effects of inhaled particu-
late compounds in animals have been
demonstrated to occur with exposure to
much higher concentrations, in particular
ifhighly insoluble particles oflow intrinsic
toxicity are considered. Those particles,
formerly characterized as "nuisance parti-
cles, can lead to acute as well as chronic
effects when the inhaled concentrations are
in the several mg/mi3 range, i.e., orders of
magnitude higher than those encountered
under human environmental exposure con-
ditions. Chronic effects observed in such
high exposure animal studies (rats appear
to be especially sensitive) include lung
inflammation, fibrosis, and even lung
tumors (23).
In animal studies it was consistently
found that at excessive exposure concentra-
tions the particle clearance function of
alveolar macrophages is severely impaired.
Retardation ofclearance appears to be due
to "overloading" of the macrophages with
phagocytized particles, thus the term "par-
ticle overload" has been used to describe
this situation (24). The significantly
retarded particle clearance results in
increased accumulation of particles in the
lung. Fibrosis and lung tumors frequently
develop in rats after such excessive expo-
sure to particles. In contrast, in other
species, such as hamsters and mice, the
same high exposures produce lower inci-
dences of inflammation and relatively few
fibrotic and no neoplastic lesions in com-
parison to rats (23,25,26).
This raises the important question as to
which animal model is the most relevant
for extrapolation to humans. Although
humans exposed to high particle concentra-
tions (e.g., coal miners) also show
inflammatory and fibrotic responses in
their lungs, no increased lung tumor inci-
dences have been observed in this particu-
lar population. Unfortunately, few studies
of the respiratory effects of coal dust on
rats have been performed. The question
then becomes: Can the results from high-
dose exposure studies in rats be used for
extrapolation to humans, or should we
restrict such extrapolations to specific
mechanistic effects that can also be demon-
strated in other species? For example, an
impairment of alveolar macrophage-medi-
ated particle clearance has been observed in
all experimental species exposed to high
concentrations of particles and may there-
fore be considered likely to also occur in
humans.
This brings us to the third question
that was listed earlier-the influence of
health status on particle-induced toxicity.
Animal studies generally are conducted in
healthy, specific pathogen-free rats, mice,
and hamsters that are bred and kept under
conditions that protect them from any
environmental hazard other than the
specific exposures being studied. In con-
trast, epidemiologic studies showing a cor-
relation between very low ambient air
particle levels and increased mortality/mor-
bidity in humans also show that the effects
are limited to individuals with compro-
mised cardiorespiratory function. Thus,
dose-response relationships observed in
healthy animals are not likely to be applica-
ble and extrapolatable to potentially more
susceptible humans, and we could be
searching for answers using the wrong ani-
mal model.
The impact ofparticle size also needs to
be considered since several studies have
shown that particles in the so-called ultra-
fine particle range (< -100 nm) have a
significantly greater adverse effect on the
lungs than larger particles (27). Ultrafine
particles are present in the ambient air and
their concentrations appear to be greater
under certain meteorologic conditions
(Castellani, personal communication) and
may therefore contribute to the observed
epidemiologic findings.
The focus of toxicologic studies on
ultrafine and larger particles has been
mainly on chronic effects; there is also evi-
dence that freshly generated polymer fumes
consisting of ultrafine particles can cause
severe acute effects, including lethality.
Paradoxically, the acute effects of
freshly generated fumes can occur at parti-
cle concentrations that are much lower
than those used in chronic particle inhala-
tion studies performed in animals (28).
These effects have been attributed to the
ultrafine particle phase rather than to the
gas phase ofpolymer fumes, and they indi-
cate that ultrafine particles may cause
severe acute effects in the lung. While
knowledge of the potential toxicity of
ultrafine particles is not sufficient to
explain the epidemiologic findings in
humans, it could form the basis for the
design ofmore detailed studies.
The paramount questions to be
addressed when trying to assess human
risks based on animal studies pertain to the
mechanistic events underlying the observed
effects. Are such mechanisms likely to be
the same in animals and humans? With
respect to particles, several investigators
have shown that the interactions of parti-
cles with inflammatory cells in the lung
lead to the production of inflammatory
mediators, cytokines, and especially reac-
tive oxidant species that in turn may be
responsible for adverse effects on other
lung cells (29). Some particles have addi-
tional toxic properties imparted by reactive
groups on their surfaces (30,31). There are
a number ofantioxidants (e.g., glutathione,
ascorbic acid, x-tocopherol, metallothio-
nein) present in different lung cells that
counteract the effects of oxidants in the
lung; however, antioxidant levels in differ-
ent animal species vary considerably
(32-34). Interspecies variability in lung
antioxidant concentrations therefore could
be responsible for the differences in suscep-
tibility observed in different animal mod-
els. In addition, the inducibility of
antioxidant systems in response to prior
exposure to oxidants may also be
significantly different, the mouse being
more responsive than the rat, for example
(33). Differences in other metabolic path-
ways, such as cytochrome P450 monooxy-
genases, may also lead to differences in
susceptibility to particle-induced toxicity in
the lung. These factors taken together may
contribute to the greater resistance to parti-
cle toxicity in one animal species versus
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another, and need to be considered when
comparing species and attempting to
extrapolate to humans.
Finally, the question ofthe mathematic
model to be used in extrapolation is a cen-
tral issue in the risk assessment process.
With respect to the above-mentioned car-
cinogenic effects ofinhaled particles in rats,
the linearized multistage model is generally
used by the U.S. EPA to define a cancer
risk (35). For inhaled particles, the unit
risk for carcinogenesis is the 95% upper-
bound of the estimated risk from continu-
ous lifetime exposure to an airborne
compound at a level of 1 pg/m3. However,
in the case of lung tumors resulting from
particle overload, it can be argued that we
may be dealing with a threshold effect, i.e.,
below a certain lung dose, no such effects
might be expected. As an example scenario,
where particles oflow solubility and inher-
ent toxicity and the clearance of the
deposited particles is not impaired, one
would not expect to see any adverse long-
term effects since no excessive accumula-
tion of particles in the lung would occur.
Indeed, long-term animal studies confirm
that when pulmonary clearance is not dis-
turbed by particle exposure, no adverse
pulmonary effects occur, thereby arguing
for the threshold model of extrapolation.
Should these findings be considered when
choosing an extrapolation model, or should
we assume that humans do not have a
threshold in their response to particle
inhalation ?
On the other hand, as mentioned previ-
ously, ultrafine particles exert their effects
at a lower concentration and are more toxic
at the same concentration than larger parti-
cles ofthe same composition, e.g., titanium
dioxide (27). If thresholds exist for parti-
cle-induced effects, do they disappear at
sufficiently small particle size? Types of
toxic effects may also differ with particle
size. In assessing human risk, it is also nec-
essary to consider that most individuals
have a preexisting particle burden. In some
cases, heavy smokers, persons exposed to
dusty environments, etc., may have suffi-
cient particle loads to inhibit clearance
(36,37). Even if a threshold for toxic
effects exists, assessment ofrisk based upon
a threshold would be inappropriate for
such individuals. It is therefore apparent
that many uncertainties exist in the low-
dose extrapolation of risk from particle
exposure.
Additional questions can be raised as to
how particles should be tested in animal
studies. Specifically, what should be the
highest dose to which rats or other labora-
tory animals are exposed in a chronic
inhalation study? The concept of maxi-
mum tolerated dose (23,38) may need to
be redefined and expanded to incorporate
the "overload" effect in the decision mak-
ing process towards the setting of air qual-
ity standards at the workplace.
This brief discussion, based mainly on
the results of animal studies, has focused
on only a few ofthe many questions related
to risk assessment, yet it shows the difficul-
ties and uncertainties surrounding the
process. Clearly, the more mechanistic data
that can be obtained for a particular
inhaled toxicant, the better our capabilities
to extrapolate animal data to humans and,
therefore, a major emphasis in the risk
assessment ofoxidant pollutants should be
placed on the elucidation of their mecha-
nism oftoxicity.
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